

June 1, 2022

Licensing Assistance Team
Division of Nuclear Material Safety
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352


RE: Radioactive materials License # 21-26488-01

To Whom It May Concern:

As we have a need to increase our number of parenterally administered therapy treatments per day, we would like to increase the maximum possession amount of material for category 10 CFR 35.300 to 6 Ci total in each of our authorized locations listed on condition 10 of our referenced license.

Should you have any questions, please feel free to contact me at 239-690-5915.

Sincerely,

A handwritten signature in black ink, appearing to read 'L. Barreca', with a large, stylized flourish at the end.

Leandro J. Barreca, MSEM
Exec. Director of Regulatory Affairs
GenesisCare USA

RECEIVED JUN 06 2022

February 23, 2021

U.S. Nuclear Regulatory Commission and
Agreement States

RE: Delegation of Authority to Make Legally Binding Statements

To Whom It May Concern:

Larry Kestin, M.D., Director of American Oncologic Associates of Michigan, P.C., Teamour S. Nurushev, DABR, Division Physics Executive-Northeast US, and Leandro J. Barreca, MSEM, Exec. Director of Regulatory Affairs, employees of GenesisCare USA, have been delegated the authority to make legally binding statements for American Oncologic Associates of Michigan, P.C. d/b/a MHP Radiation Oncology Institute with regards to: 1) registration of radiation producing machines and radioactive materials licenses applications with the Nuclear Regulatory Commission; and 2) inspections, renewals, amendments, and terminations involving the Nuclear Regulatory Commission. This delegation may be revoked at any time by American Oncologic Associates of Michigan, P.C.

Sincerely,


jeff Margolis (Feb 24, 2021 16:49 EST)

Jeffrey Margolis, M.D.
President
American Oncologic Associates of Michigan, P.C.

RECEIVED JUN 06 2022